Moderna TX: A Phase 1/2a Open-Label Dose-Ranging and Observer-Blind Placebo-Controlled, Safety and Immunogenicity Study of mRNA-1647 Cytomegalovirus Vaccine in Female and Male Participants 9 to 15 Years of Age and Participants 16 to 25...

Project: Research

Status	Active
Effective start/end date	05/23/23 → 06/18/26

Project Details